On 25 September 2026 the FDA approved a supplement to the new drug application for baricitinib (Olumiant), held by Eli Lilly. The notice does not say what the supplement changes.
Baricitinib is a JAK inhibitor used in rheumatoid arthritis, alopecia areata and some other inflammatory conditions. Its relevance to oncology is safety: JAK inhibitor labelling in the USA carries a boxed warning that includes malignancy, alongside serious infection, major cardiovascular events and thrombosis. The supplement's content and any CDSCO action are not stated.
- The notice confirms an approved supplement but not its content.
- Ask about JAK inhibitor use when taking a history from a patient with a new cancer diagnosis.
- JAK inhibitor labelling in the USA carries a boxed warning that includes malignancy.
- Check the revised label before assuming any change.
Why it matters
Oncologists increasingly see patients exposed to JAK inhibitors, and labelling on malignancy risk is part of that history.
Don't overread it
A licence supplement is not, on its own, a new safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free